Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.
Abstract
<h4>Background</h4>Whether to repair nonsevere tricuspid regurgitation (TR) during
surgery for ischemic mitral valve regurgitation (IMR) remains uncertain.<h4>Objectives</h4>The
goal of this study was to investigate the incidence, predictors, and clinical significance
of TR progression and presence of ≥moderate TR after IMR surgery.<h4>Methods</h4>Patients
(n = 492) with untreated nonsevere TR within 2 prospectively randomized IMR trials
were included. Key outcomes were TR progression (either progression by ≥2 grades,
surgery for TR, or severe TR at 2 years) and presence of ≥moderate TR at 2 years.<h4>Results</h4>Patients'
mean age was 66 ± 10 years (67% male), and TR distribution was 60% ≤trace, 31% mild,
and 9% moderate. Among 2-year survivors, TR progression occurred in 20 (6%) of 325
patients. Baseline tricuspid annular diameter (TAD) was not predictive of TR progression.
At 2 years, 37 (11%) of 323 patients had ≥moderate TR. Baseline TR grade, indexed
TAD, and surgical ablation for atrial fibrillation were independent predictors of ≥moderate
TR. However, TAD alone had poor discrimination (area under the curve, ≤0.65). Presence
of ≥moderate TR at 2 years was higher in patients with MR recurrence (20% vs. 9%;
p = 0.02) and a permanent pacemaker/defibrillator (19% vs. 9%; p = 0.01). Clinical
event rates (composite of ≥1 New York Heart Association functional class increase,
heart failure hospitalization, mitral valve surgery, and stroke) were higher in patients
with TR progression (55% vs. 23%; p = 0.003) and ≥moderate TR at 2 years (38% vs.
22%; p = 0.04).<h4>Conclusions</h4>After IMR surgery, progression of unrepaired nonsevere
TR is uncommon. Baseline TAD is not predictive of TR progression and is poorly discriminative
of ≥moderate TR at 2 years. TR progression and presence of ≥moderate TR are associated
with clinical events. (Comparing the Effectiveness of a Mitral Valve Repair Procedure
in Combination With Coronary Artery Bypass Grafting [CABG] Versus CABG Alone in People
With Moderate Ischemic Mitral Regurgitation, NCT00806988; Comparing the Effectiveness
of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic
Ischemic Mitral Regurgitation, NCT00807040).
Type
Journal articlePermalink
https://hdl.handle.net/10161/22842Published Version (Please cite this version)
10.1016/j.jacc.2020.11.066Publication Info
Bertrand, Philippe B; Overbey, Jessica R; Zeng, Xin; Levine, Robert A; Ailawadi, Gorav;
Acker, Michael A; ... Cardiothoracic Surgical Trials Network (CTSN) (2021). Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.
Journal of the American College of Cardiology, 77(6). pp. 713-724. 10.1016/j.jacc.2020.11.066. Retrieved from https://hdl.handle.net/10161/22842.This is constructed from limited available data and may be imprecise. To cite this
article, please review & use the official citation provided by the journal.
Collections
More Info
Show full item recordScholars@Duke
Peter Kent Smith
Mary and Deryl Hart Distinguished Professor of Surgery, in the School of Medicine
Dr. Smith is the Prinicpal Investigator for the Duke site in the Cardiothoracic Surgery
Clinical Trials Network (CTSN) and in recent years has focused his research efforts
in clinical research. The CTSN is an NHLBI sponsored network developed to promote
clinical research in cardiac surgery, and is now entering its 7th year of funding
with a commitment now for an additional 5 years. Dr. Smith is the national PI for
a randomized clinical trial comparing CABG alone to CABG with mitral repair f

Articles written by Duke faculty are made available through the campus open access policy. For more information see: Duke Open Access Policy
Rights for Collection: Scholarly Articles
Works are deposited here by their authors, and represent their research and opinions, not that of Duke University. Some materials and descriptions may include offensive content. More info